Abuse Deterrent Formulation Technologies Market, 2030

DUBLIN, Oct. 7, 2019 /PRNewswire/ -- The "Abuse Deterrent Formulation Technologies Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

The 'Abuse-Deterrent Formulation Technologies Market, 2019-2030' report features an extensive study of the current market landscape and the future potential of industry players that are offering various abuse-deterrent formulation technologies to different pharmaceutical companies.

According to the Centers for Disease Control and Prevention (CDC), more than 72,000 overdose-related deaths were reported in 2017, of which close to 50,000 involved the use of an opioid. Moreover, opioid abuse was estimated to have been responsible for an economic deficit of over USD 500 billion, related to loss of productivity and healthcare costs, in the US. Other drug classes that are prone to abuse include antidepressants and central nervous system (CNS) stimulants.

In 2017, close to 17,000 deaths were reported to have been the result of an overdose of prescription antidepressants. Most of these deaths (~11,500) involved the misuse of benzodiazepines, such as VALIUM (diazepam) and XANAX (alprazolam). CNS stimulants are usually indicated for the treatment of patients suffering from attention-deficit / hyperactivity disorder (ADHD). Among the various overdose-related deaths which took place in 2017, it is worth highlighting that over 12% involved the use of psychostimulants.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on likely licensing deal structures and agreements that are expected to be signed between drug and technology developers in the foreseen future, we have provided an informed estimate on the likely evolution of the market for the period 2019-2030.

The report features likely distribution of the current and forecasted financial opportunity across

• [A] target drug class (opioids, antidepressants and CNS stimulants)
• [B] abuse deterrence approach (physical / chemical barriers, agonist / antagonist combinations, aversion approach, prodrug approach, abuse-deterrent drug delivery systems and others)
• [C] type of end product (tablets, capsules, transdermal patches, thin films and others)
• [D] geography (North America, Europe, Asia Pacific and the rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Prescription Drug Abuse / Misuse
3.3. Commonly Abused Drug Classes
3.3.1. Opioids
3.3.2. Antidepressants
3.3.3. Central Nervous System (CNS) Stimulants
3.4. Preliminary Strategies to Prevent Abuse
3.4.1. Role of Healthcare Authorities / Policy Makers
3.4.2. Role of Pharmacists
3.4.3. Role of Clinicians
3.4.4. Role of Patients
3.5. Abuse Deterrent Formulations and Affiliated Technologies
3.5.1. Types of Abuse Deterrent Formulation Approaches
3.5.1.1. Physical and Chemical Barriers
3.5.1.2. Prodrug Approach
3.5.1.3. Chemical Agonists / Antagonists
3.5.1.4. Aversion
3.5.1.5. Drug Delivery Systems
3.5.1.6. Others
3.6. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Abuse Deterrent Formulation Technologies: Overall Market Landscape

5. COMPETITIVENESS ANALYSIS OF TECHNOLOGY PLATFORMS
5.1. Chapter Overview
5.2. Methodology
5.3. Platform Competitiveness Analysis

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Acura Pharmaceuticals
6.3. Altus Formulation
6.4. BioDelivery Sciences International
6.5. CIMA LABS (acquired by Teva Pharmaceutical)
6.6. Elysium Therapeutics
6.7. Grnenthal
6.8. Intellipharmaceutics
6.9. Purdue Pharma
6.10. TITAN Pharmaceuticals

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Abuse Deterrent Formulation Technologies: Analysis of Patent Portfolio
7.4. Abuse-Deterrent Formulation Technologies: Patent Benchmarking Analysis

8. RECENT PARTNERSHIPS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Abuse-Deterrent Formulation Technologies: List of Partnerships and Collaborations

9. LIKELY DRUG CANDIDATES FOR DEVELOPMENT OF ABUSE DETERRENT ALTERNATIVES
9.1. Chapter Overview
9.2. Likely Candidates for ADFs: Opioids
9.3. Likely Candidates for ADFs: Antidepressants
9.4. Likely Candidates for ADFs: CNS Stimulants
9.5. Concluding Remarks

10. MARKET SIZING AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Abuse-Deterrent Technologies Market, 2019-2030
10.4. Abuse-Deterrent Technologies Market: Distribution by Upfront and Milestone Payments, 2019-2030
10.5. Abuse Deterrent Technologies Market: Distribution by Drug Class, 2019-2030
10.6. Abuse Deterrent Technologies Market: Distribution by Abuse Deterrence Approach, 2019-2030
10.7. Abuse Deterrent Technologies Market: Distribution by Type of End Product, 2019-2030
10.8. Abuse Deterrent Technologies Market: Geographical Distribution, 2019-2030
10.9. Concluding Remarks

11. CONCLUSION

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. Elysium Therapeutics
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Greg Sturmer, Chief Executive Officer
12.3. Lucideon
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Aia Malik, Commercial Development Manager, Healthcare

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

• 4P Therapeutics (subsidiary of Nutriband)
• Acella Pharmaceuticals
• Acura Pharmaceuticals
• Adello Biologics
• Aesica Pharmaceuticals
• Alitair Pharmaceuticals
• Altus Formulation
• Aquestive Therapeutics
• Assertio Therapeutics
• Atlantic Pharmaceuticals
• Avadel Pharmaceuticals
• Bayer
• BioDelivery Sciences International
• Buzzz Pharmaceuticals
• Camargo Pharmaceutical Services
• Capsugel
• Cassava Sciences
• Catalent
• CIMA LABS (acquired by Teva)
• Coating Place
• Collegium Pharmaceutical
• Currax Pharmaceuticals
• Daiichi Sankyo
• DURECT
• Egalet
• Elite Pharmaceuticals
• Elysium Therapeutics
• Emplicure
• Encap Drug Delivery
• Endo Pharmaceuticals
• Ensysce Biosciences
• Epic Pharma
• Ethypharm
• ExxPharma Therapeutics
• Genus Lifesciences
• Glenmark Pharmaceuticals
• Grnenthal
• Indivior
• Inspirion Delivery Sciences
• Intalere
• Intellipharmaceutics
• inVentiv Health
• Janssen Pharmaceuticals
• Johnson & Johnson
• Kashiv BioSciences
• KemPharm
• KVK Tech
• Lannett
• Lonza
• Lucideon
• MainPointe Pharmaceuticals
• Mallinckrodt Pharmaceuticals
• Memorial Sloan Kettering Cancer Center
• Mundipharma
• Nektar Therapeutics
• Neos Therapeutics
• New River Pharmaceuticals
• Nutriband
• Optum (part of UnitedHealth Group)
• Orexo
• Patheon
• Pernix Therapeutics
• Pfizer
• Pop Test
• Praxis Bioresearch
• Publicis Touchpoint Solutions
• Purdue Pharma
• QRxPharma
• Quivive Pharma
• Recipharm
• Relmada Therapeutics
• Shionogi
• Shire
• Signature Therapeutics
• Skyepharma
• SPARC
• SunGen Pharma
• Tetra Bio-Pharma
• Teva Pharmaceutical
• TITAN Pharmaceuticals
• Tris Pharma
• twoXAR
• University of Nebraska Medical Center
• Zogenix

For more information about this report visit https://www.researchandmarkets.com/r/dev8ht

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com